Citations

Clear

43 citation(s) found for "Hook, Christopher".

Introduction to Disability and Health for Preclinical Medical Students: Didactic and Disability Panel Discussion
Rogers, Julie M.G. , Morris, Megan A. , Hook, C. Christopher , Havyer, Rachel D. , Rogers, Julie M.

Mayo Clinic

MedEdPORTAL | July 21, 2016 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.15766/mep_2374-8265.10429 | PMID 31008209 Get It

Successful Percutaneous Nephrolithotomy in Patients with Immune-Mediated Thrombocytopenia Treated with Romiplostim
McCall, Andrew N., Ingimarsson, Johann P. , Morrisson, Griffin T., Hook, C. Christopher , Krambeck, Amy E. , Hook, Christopher C.

Mayo Clinic

Journal of Endourology Case Reports | April 28, 2016 | Volume: 2 | Issue: 1 | Pages: 81-83

10.1089/cren.2016.0048 | PMID 27579425 Get It

Abstract Background: Percutaneous nephrolithotomy (PCNL) for large stone burden can be problematic in patients with significant risk of bleeding complications, specifically thrombocytopenia. This report demonstrates effective correction of two patients' thrombocytopenia, subsequently leading to removal of large stone burden through PCNL. Case Presentation: We present two Middle Eastern patients who presented with medical histories significant for thrombocytopenia, secondary to splenomegaly and hepatic vein thrombosis, and large volume nephrolithiasis. Patient 1 is a 65-year-old female with a right 5 cm stone and a platelet count of 34,000. Patient 2 is a 45-year-old female with a 3 cm left staghorn stone and a platelet count of 44,000. After consultation with hematology, both underwent therapy with prednisone and intravenous immunoglobulin without improvement in their platelet count. They then received 3 μg/kg/dose of romiplostim weekly that improved their platelet counts to 133,000 and 195,000 in 2 weeks, respectively. Patient 1's PCNL was completed in a single-stage procedure with stone-free status shown on CT postoperative day 1. Patient 2 underwent PCNL and a secondary ureteroscopy for residual stone fragments on postoperative day 2. Both patients experienced no complication during the procedure, hospital stay, or postoperative course. Both continued romiplostim for 20 days postoperatively with platelet levels returning to their baseline range after 1 month. Conclusion: In the appropriately selected patient, romiplostim can correct thrombocytopenia enough to safely and effectively perform PCNL in patients with underlying hematologic disorders. Close coordination between urology and hematology is imperative to ensure an effective outcome in this challenging patient population.
Clinical course of patients with incidental finding of 20q‐ in the bone marrow without a morphologic evidence of myeloid neoplasm
Jawad, Majd, Oliveira, Jennifer L. , Hoyer, James D., Hook, C. Christopher , Herrick, Jennifer L. , Jawad, Majd D, Shi, Min , Go, Ronald S.

Mayo Clinic

American Journal of Hematology | March 1, 2016 | Volume: 91 | Issue: 6 | Pages: 556-559

10.1002/ajh.24347 | PMID 26928533 Get It

Deletion of the long arm of chromosome 20 (20q‐) is a frequent finding in bone marrow karyotypes, mainly associated with myeloid neoplasms (MNs). Its clinical significance in the setting of normal bone marrow morphology is unclear. We described the clinical characteristics, cytogenetic findings, and outcome of 102 such patients seen at our institution from 2000‐2014. Their median age was 66 years. The indication for bone marrow biopsy was either unexplained cytopenias (48%) or hematologic cancer staging/reevaluation (52%). In 88 (86%) patients, 20q‐ was an isolated finding. Thirty‐nine (38%) patients previously received chemotherapy and 88 (86%) had cytopenias at the time of 20q‐ finding. After a median of 35 months, 12 (13%) patients developed MNs: 10 myelodysplastic syndromes, one acute myeloid leukemia and one myeloproliferative neoplasm. None of 14 patients with normal blood counts, but 7 of 35 (20%) with mild cytopenias, and 5 of 53 (9%) with moderate/severe cytopenias developed MNs. We did not find an association between the number of metaphases with 20q‐ and the development of MN. The incidental finding of 20q‐ in the bone marrow generally does not portend an early stage MN. Particularly, those without cytopenias at the time of diagnosis may have a good prognosis. Am. J. Hematol. 91:556–559, 2016. © 2016 Wiley Periodicals, Inc.